proxyvotesnow.com

Home › Companies › Phathom Pharmaceuticals, Inc. › 2025-2026

Phathom Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Phathom Pharmaceuticals, Inc.’s Form 8-K, filed 2026-05-21 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 5Ballot items
  • 184Asset managers
  • 1,042Fund votes
  • 2026-05-19Meeting date

Proxy season: 2024-2025 2025-2026

Explore Phathom Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Phathom Pharmaceuticals, Inc.

These tallies are Phathom Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-21 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Phathom Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2026-05-19
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Steven Basta 42,656,800---- 4,490,78117,487,652 Majority: yes
Elect Director: Theodore R. Schroeder 42,578,532---- 4,569,04917,487,652 Majority: yes
Elect Director: Mark Stenhouse 41,249,990---- 5,897,59117,487,652 Majority: yes
Proposal 2: Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal 2026: 64,482,75749,661102,815 ---- Majority: yes
Proposal 3: Approval of the Compensation of the Named Executive Officers ("say-on-pay") The Company's stockholders voted and approved, on a non-binding, advisory basis, the compensation of the named executive officers: 44,449,7612,532,145165,675 --17,487,652 Majority: yes

Source: Phathom Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-05-21 — read the filing on EDGAR.

How asset managers voted at the Phathom Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 184 asset managers that disclosed a Phathom Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay").

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 13 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 44,449,761AGAINST: 2,532,145

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Approval of the Compensation of the Named Executive Officers ("say-on-pay") The Company's stockholders voted and approved, on a non-binding, advisory basis, the compensation of the named executive officers:”): 44,449,761 for, 2,532,145 against, per its Form 8-K filed 2026-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 79,442,367 outstanding shares: 56% for, 3% against (59% of the company cast a for/against vote).

The 183 asset managers below cast 95% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 95%
FOR: 94.6%AGAINST: 5.3%ABSTAIN: 0.0%
Largest asset managers voting on “To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay").” at Phathom Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Frazier Life Sciences Management, L.P.12,466,4890 00For
Medicxi Ventures Management (Jersey) Ltd7,464,5720 00For
Invesco6,464,414626,422 00For
Carlyle Group Inc.3,496,8080 00For
NEA Management Company, LLC1,960,1690 00For
Vanguard1,810,7231,259 00For
Ensign Peak Advisors, Inc1,807,5800 00For
683 Capital Management, LLC1,679,0830 00For
BlackRock1,246,00598,591 00For
WASATCH ADVISORS LP1,337,9610 00For
WASATCH FUNDS TRUST1,321,1590 00For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST1,066,4800 00For
Charles Schwab816,9530 00For
FRANKLIN ADVISERS INC787,6840 00For
Waddell & Reed727,4250 00For
PERCEPTIVE ADVISORS LLC694,5220 00For
GW&K Investment Management, LLC0686,873 00Against
EcoR1 Capital, LLC625,0000 00For
Fidelity341,964264,087 00For
Catalio Capital Management, LP586,0410 00For
State Street533,757894 00For
GEODE CAPITAL MANAGEMENT, LLC486,6780 00For
Woodline Partners LP362,1210 00For
Jackson National320,6450 00For
FRANKLIN STRATEGIC SERIES285,2710 00For

Showing the 25 largest of 183 asset managers. See all 183 in the interactive database.

2. To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Steven Basta

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%
FOR: 42,656,800WITHHELD: 4,490,781

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Steven Basta”): 42,656,800 for, 4,490,781 withheld, per its Form 8-K filed 2026-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 79,442,367 outstanding shares: 53.7% for, 6% withheld (59% of the company cast a for/withheld vote).

The 53 asset managers below cast 100% of the shares they voted on this item FOR (10,353,923 for, 0 against).

FOR 88%12%
FOR: 10,353,923 (87.8%)ABSTAIN: 1,434,241 (12.2%)
Largest asset managers voting on “To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Steven Basta” at Phathom Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Invesco2,973,3310 00For
Vanguard1,712,4840 60For
Catalys Pacific, LLC1,493,8540 00For
WASATCH FUNDS TRUST1,321,1590 00For
Waddell & Reed00 727,4250Abstain
Fidelity598,1590 3,8580For
Charles Schwab408,4730 00For
BlackRock353,7260 00For
Jackson National320,6450 00For
FRANKLIN STRATEGIC SERIES00 285,2710Abstain
Simplify Exchange Traded Funds262,3860 00For
Equitable246,6600 00For
Brighthouse158,1970 23,1060For
Ivy Variable Insurance Portfolios00 136,7850Abstain
Securian Funds Trust00 116,5720Abstain
QUANTITATIVE MASTER SERIES LLC74,8570 00For
Goldman Sachs56,1410 00For
JPMorgan54,5040 00For
ETFis Series Trust I00 53,5010Abstain
AMG Funds IV38,2680 00For
State Street36,7570 290For
Russell Investments35,2710 00For
Lincoln Financial33,4660 00For
MassMutual33,2200 00For
SEI30,5760 00For

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

3. To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Mark Stenhouse

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%13%
FOR: 41,249,990WITHHELD: 5,897,591

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Mark Stenhouse”): 41,249,990 for, 5,897,591 withheld, per its Form 8-K filed 2026-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 79,442,367 outstanding shares: 51.9% for, 7% withheld (59% of the company cast a for/withheld vote).

The 52 asset managers below cast 100% of the shares they voted on this item FOR (8,307,410 for, 0 against).

FOR 81%ABSTAIN 19%
FOR: 8,307,410 (80.7%)ABSTAIN: 1,986,900 (19.3%)
Largest asset managers voting on “To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Mark Stenhouse” at Phathom Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Invesco2,973,3310 00For
Vanguard1,711,2260 1,2630For
WASATCH FUNDS TRUST1,321,1590 00For
Waddell & Reed00 727,4250Abstain
Fidelity598,1590 3,8580For
Charles Schwab00 408,4730Abstain
BlackRock353,7260 00For
Jackson National320,6450 00For
FRANKLIN STRATEGIC SERIES00 285,2710Abstain
Simplify Exchange Traded Funds262,3860 00For
Equitable216,8800 29,7800For
Brighthouse158,1970 23,1060For
Ivy Variable Insurance Portfolios00 136,7850Abstain
Securian Funds Trust00 116,5720Abstain
QUANTITATIVE MASTER SERIES LLC74,8570 00For
Goldman Sachs56,1410 00For
JPMorgan54,5040 00For
ETFis Series Trust I00 53,5010Abstain
AMG Funds IV38,2680 00For
State Street36,7570 290For
Russell Investments00 35,2710Abstain
Lincoln Financial33,4660 00For
MassMutual33,2200 00For
SEI00 30,5760Abstain
ProShares00 27,4350Abstain

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

4. To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Theodore R. Schroeder

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%
FOR: 42,578,532WITHHELD: 4,569,049

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Theodore R. Schroeder”): 42,578,532 for, 4,569,049 withheld, per its Form 8-K filed 2026-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 79,442,367 outstanding shares: 53.6% for, 6% withheld (59% of the company cast a for/withheld vote).

The 52 asset managers below cast 100% of the shares they voted on this item FOR (8,830,289 for, 0 against).

FOR 86%ABSTAIN 14%
FOR: 8,830,289 (85.8%)ABSTAIN: 1,464,021 (14.2%)
Largest asset managers voting on “To elect three class I directors to hold office until the 2029 Annual Meeting of Stockholders: Theodore R. Sch” at Phathom Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Invesco2,973,3310 00For
Vanguard1,712,4840 60For
WASATCH FUNDS TRUST1,321,1590 00For
Waddell & Reed00 727,4250Abstain
Fidelity598,1590 3,8580For
Charles Schwab408,4730 00For
BlackRock353,7260 00For
Jackson National320,6450 00For
FRANKLIN STRATEGIC SERIES00 285,2710Abstain
Simplify Exchange Traded Funds262,3860 00For
Equitable216,8800 29,7800For
Brighthouse158,1970 23,1060For
Ivy Variable Insurance Portfolios00 136,7850Abstain
Securian Funds Trust00 116,5720Abstain
QUANTITATIVE MASTER SERIES LLC74,8570 00For
Goldman Sachs56,1410 00For
JPMorgan54,5040 00For
ETFis Series Trust I00 53,5010Abstain
AMG Funds IV38,2680 00For
State Street36,7570 290For
Russell Investments35,2710 00For
Lincoln Financial33,4660 00For
MassMutual33,2200 00For
SEI30,5760 00For
ProShares00 27,4350Abstain

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

5. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 64,482,757AGAINST: 49,661

Phathom Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: Ratification of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal”): 64,482,757 for, 49,661 against, per its Form 8-K filed 2026-05-21 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 79,442,367 outstanding shares: 81% for, 0.1% against (81% of the company cast a for/against vote).

The 52 asset managers below cast 100% of the shares they voted on this item FOR (10,288,364 for, 0 against).

FOR 99.9%
FOR: 10,288,364 (99.9%)ABSTAIN: 5,946 (0.1%)
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ” at Phathom Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Invesco2,973,3310 00For
Vanguard1,712,4900 00For
WASATCH FUNDS TRUST1,321,1590 00For
Waddell & Reed727,4250 00For
Fidelity602,0170 00For
Charles Schwab408,4730 00For
BlackRock353,7260 00For
Jackson National320,6450 00For
FRANKLIN STRATEGIC SERIES285,2710 00For
Simplify Exchange Traded Funds262,3860 00For
Equitable246,6600 00For
Brighthouse175,3570 5,9460For
Ivy Variable Insurance Portfolios136,7850 00For
Securian Funds Trust116,5720 00For
QUANTITATIVE MASTER SERIES LLC74,8570 00For
Goldman Sachs56,1410 00For
JPMorgan54,5040 00For
ETFis Series Trust I53,5010 00For
AMG Funds IV38,2680 00For
State Street36,7860 00For
Russell Investments35,2710 00For
Lincoln Financial33,4660 00For
MassMutual33,2200 00For
SEI30,5760 00For
ProShares27,4350 00For

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Largest Phathom Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked by the number of Phathom Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 79,442,367 shares outstanding at the time of that meeting.

Top Phathom Pharmaceuticals, Inc. shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1Frazier Life Sciences Management, L.P. 15.69%
2Medicxi Ventures Management (Jersey) Ltd 9.40%
3Invesco 8.93%
4Carlyle Group Inc. 4.40%
5NEA Management Company, LLC 2.47%
6Vanguard 2.28%
7Ensign Peak Advisors, Inc 2.28%
8683 Capital Management, LLC 2.11%
9BlackRock 1.69%
10WASATCH ADVISORS LP 1.68%

Reported Phathom Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Phathom Pharmaceuticals, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
Invesco 5.44% 13F
BlackRock 5.11% 13F
Millennium Management 5.06% 13F
Vanguard Group 4.00% 13F
State Street 1.75% 13F
Geode Capital 1.67% 13F
Franklin Templeton 1.25% 13F
Citadel Advisors 1.16% 13F
Goldman Sachs 0.79% 13F
Two Sigma 0.61% 13F

Percentages above are of 79,442,367 shares outstanding, as reported by Phathom Pharmaceuticals, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Phathom Pharmaceuticals, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Phathom Pharmaceuticals, Inc.'s shareholder meeting held 2026-05-19, in the 2025-2026 proxy season, 184 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,042 separate fund positions. On the most widely held item on that ballot — To approve the compensation of the named executive officers on a non-binding advisory basis… — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Phathom Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-21.

Phathom Pharmaceuticals, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).